Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis...
July 01, 2021 16:15 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

- New data include update from the fourth patient treated in the Phase 1/2 trial - Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response ...
June 03, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Participate in Upcoming Investor Conferences

PITTSBURGH, June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two...
May 10, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4...
May 03, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth...
April 27, 2021 16:35 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...
April 26, 2021 16:05 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the...
April 19, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosisCompany expands rare genetic lung disease pipeline with KB408 for the...
March 30, 2021 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete...
March 29, 2021 16:30 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Participate in Upcoming Investor Conferences

PITTSBURGH, March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two...